These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 6793628

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Molecular heterogeneity of Hageman trait (factor XII deficiency): evidence that two of 49 subjects are cross-reacting material positive (CRM+).
    Saito H, Scott JG, Movat HZ, Scialla SJ.
    J Lab Clin Med; 1979 Aug; 94(2):256-65. PubMed ID: 110893
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A rapid purification with high recovery of factor XII (Hageman factor) on immunoaffinity column: application to an abnormal clotting factor XII (factor XIITORONTO).
    Takahashi I, Saito H.
    J Biochem; 1988 Apr; 103(4):641-3. PubMed ID: 3139646
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Structural changes accompanying enzymatic activation of human Hageman factor.
    Revak SD, Cochrane CG, Johnston AR, Hugli TE.
    J Clin Invest; 1974 Sep; 54(3):619-27. PubMed ID: 4277669
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Functional characterization of an abnormal factor XII molecule (F XII Bern).
    Wuillemin WA, Huber I, Furlan M, Lämmle B.
    Blood; 1991 Aug 15; 78(4):997-1004. PubMed ID: 1868256
    [Abstract] [Full Text] [Related]

  • 9. Characterization of a variant prekallikrein, prekallikrein Long Beach, from a family with mixed cross-reacting material-positive and cross-reacting material-negative prekallikrein deficiency.
    Bouma BN, Kerbiriou DM, Baker J, Griffin JH.
    J Clin Invest; 1986 Jul 15; 78(1):170-6. PubMed ID: 3487556
    [Abstract] [Full Text] [Related]

  • 10. The autoactivation of rabbit Hageman factor.
    Wiggins RC, Cochrane CC.
    J Exp Med; 1979 Nov 01; 150(5):1122-33. PubMed ID: 501286
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Purification of high molecular weight kininogen and the role of this agent in blood coagulation.
    Saito H.
    J Clin Invest; 1977 Sep 01; 60(3):584-94. PubMed ID: 893664
    [Abstract] [Full Text] [Related]

  • 13. The role of prekallikrein and high-molecular-weight kininogen in the contact activation of Hageman factor (factor XII) by sulfatides and other agents.
    España F, Ratnoff OD.
    J Lab Clin Med; 1983 Oct 01; 102(4):487-99. PubMed ID: 6604770
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells.
    Wiggins RC, Loskutoff DJ, Cochrane CG, Griffin JH, Edgington TS.
    J Clin Invest; 1980 Jan 01; 65(1):197-206. PubMed ID: 6444222
    [Abstract] [Full Text] [Related]

  • 19. Interactions among Hageman factor (HG, Factor XII), plasma thromboplastin antecedent (PTA, Factor XI), plasma prekallikrein (PK, Fletcher factor) and high molecular weight kininogen (HMW-K, Fitzgerald factor) in blood coagulation.
    Saito H, Ratnoff OD.
    Adv Exp Med Biol; 1979 Jan 01; 120B():61-70. PubMed ID: 517254
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.